Physician profile

Scott P Stein

Rheumatology · Victoria, TX

NPI 1659453306

$14,246.05

in general payments reported to CMS, 2019-2025

38 companies · $2,243 in 2025

The $2,243 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$6,495.40
Education$318.52

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $2,654.75 2019-2025 Tavneos, Enbrel, Otezla
Abbvie INC. $1,835.87 2019-2025 Rinvoq, Skyrizi
Aurinia Pharma U.S., INC. $1,382.10 2021-2024 Lupkynis
Mallinckrodt Hospital Products INC. $1,194.73 2020-2025 Acthar
Astrazeneca Pharmaceuticals LP $1,086.95 2021-2025 Saphnelo
Radius Health, INC. $757.39 2019-2025 Tymlos
Janssen Biotech, INC. $722.35 2019-2025 Tremfya, Simponi, Simponi Aria
Novartis Pharmaceuticals Corporation $574.01 2019-2025
Horizon Therapeutics Plc $571.31 2019-2022
E.R. Squibb & Sons, L.L.C. $486.67 2019-2025 Orencia
Lilly USA, LLC $458.51 2019-2025 Taltz
Ucb, INC. $375.77 2019-2025 Bimzelx, Cimzia
Pfizer INC. $314.61 2019-2025
Intercept Pharmaceuticals, INC. $272.93 2021-2025 Ocaliva
Boehringer Ingelheim Pharmaceuticals, INC. $174.50 2019-2025 Cyltezo, Ofev
Show all 38 companies
CompanyGeneral paymentsYearsTop products
Celgene Corporation $136.05 2019
Mallinckrodt Enterprises LLC $121.89 2019
Merck Sharp & Dohme LLC $111.05 2021-2023 Belsomra
Genzyme Corporation $106.54 2019-2024
Glaxosmithkline, LLC. $101.52 2020-2025 Benlysta
Gilead Sciences, INC. $98.45 2025
Ani Pharmaceuticals, INC. $93.02 2022-2024 Purified Cortrophin Gel
Madrigal Pharmaceuticals $84.99 2024-2025 Rezdiffra, Resmetirom
Medtronic USA, INC. $69.13 2019
United Therapeutics Corporation $67.46 2021
Genentech USA, INC. $59.76 2019-2025 Gazyva
Janssen Pharmaceuticals, INC $49.43 2019
Octapharma USA, INC. $49.04 2022
Kowa Pharmaceuticals America, INC. $43.49 2022
Idorsia Pharmaceuticals US INC $40.78 2022-2023 Quviviq
Sandoz INC. $28.99 2024 Hyrimoz
Neurocrine Biosciences, INC. $27.78 2022
Azurity Pharmaceuticals, INC. $20.20 2024
Takeda Pharmaceuticals U.S.A., INC. $19.14 2023 Vpriv
Fresenius Kabi USA, LLC $14.31 2024 Idacio
Strongbridge US INC. $13.99 2020
Arbor Pharmaceuticals, INC. $13.80 2021
Biohaven Pharmaceutical Holding Company LTD. $12.79 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Scott P Stein

$14,246.05

in general payments reported 2019-2025

Years
2019-2025
Top company
Amgen INC.
Context
The $2,243 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).

https://glasscript.com/doctor/302400/scott-p-stein

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.